The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | C | Cardiovascular system | |
| 2 | C01 | Cardiac therapy | |
| 3 | C01B | Antiarrhythmics, class I and III | |
| 4 | C01BG | Other class I antiarrhythmics |
| Code | Title | |
|---|---|---|
| C01BG01 | Moracizine | |
| C01BG07 | Cibenzoline | |
| C01BG11 | Vernakalant |
| Active Ingredient | Description | |
|---|---|---|
| Vernakalant |
Vernakalant is an antiarrhythmic medicine that acts preferentially in the atria to prolong atrial refractoriness and to rate-dependently slow impulse conduction. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| BRIVANESS Concentrate for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC |